PSA Test and Prostate Health: What Men Should Know

Prostate health is a central concern for men considering testosterone therapy — and for all men over 40. PSA (prostate-specific antigen) testing is the primary screening tool for prostate cancer and a mandatory monitoring marker for men on testosterone therapy. Understanding what PSA measures, how to interpret it, and what TRT's actual relationship to prostate health is will help you navigate this topic with confidence.

What PSA Measures

PSA is a protein produced by both normal and malignant prostate cells. It is normally present in small amounts in the blood, but elevated PSA suggests prostate inflammation (prostatitis), benign prostatic hyperplasia (BPH), or prostate cancer. PSA is not cancer-specific — which is why elevated results require careful interpretation rather than alarm.

What is a PSA test and why do men need it?

PSA (prostate-specific antigen) is a protein produced by prostate cells. Elevated or rising PSA can indicate prostate inflammation, benign enlargement, or cancer. For men on testosterone therapy, PSA monitoring is essential because testosterone stimulates prostate tissue and can reveal pre-existing conditions.

PSA Reference Ranges	Age	Normal PSA (ng/mL)
Consider Evaluation	40–49	< 2.5
≥ 2.5	50–59	< 3.5
≥ 3.5	60–69	< 4.5
≥ 4.5	70+	< 6.5
≥ 6.5	PSA Velocity Matters

Does testosterone therapy cause prostate cancer?

Current evidence does not support that TRT causes prostate cancer. Testosterone does stimulate prostate tissue, which is why PSA monitoring is important. Historical concerns from the 'androgen hypothesis' have been substantially revised—men on TRT show prostate cancer rates comparable to age-matched peers when properly screened.

A single PSA value is less informative than the trend over time. PSA velocity — the rate of change per year — is a significant red flag. A rise of more than 0.75 ng/mL per year warrants evaluation regardless of absolute value. This is why baseline testing (ideally by age 40) and annual monitoring provide the most clinically useful data.

Testosterone and PSA: Clearing Up the Myth

The historical concern that TRT causes prostate cancer has not been supported by the evidence. Multiple large studies and meta-analyses show no increased risk of prostate cancer with testosterone therapy. PSA typically rises modestly in the first 3–6 months of TRT (due to prostate tissue responding to normalized testosterone), then plateaus. This initial rise does not represent malignancy and should not prompt discontinuation of appropriate therapy.

How often should men on TRT get PSA testing?

PSA should be tested at baseline before starting TRT, then at 3 months, 6 months, and annually thereafter. A rise of more than 1.4 ng/mL above baseline within the first year of TRT warrants urological evaluation. Annual monitoring continues as long as therapy is maintained.

TRT is contraindicated in men with diagnosed prostate cancer. Men with a family history of prostate cancer should have thorough prostate evaluation before starting and ongoing monitoring while on TRT.

At what PSA level should men be concerned?

PSA above 4.0 ng/mL warrants evaluation in most men. For younger men (under 50), the threshold is lower—above 2.5 ng/mL. The rate of change (PSA velocity) matters as much as the absolute number. A rapid rise even within the 'normal' range can indicate a problem requiring investigation.

Monitoring Protocol on TRT

• Baseline PSA before starting TRT (mandatory)

• PSA at 3–6 months after starting

• Annual PSA thereafter

• Referral to urology if PSA rises more than 1.4 ng/mL in any 12-month period

• Digital rectal exam (DRE) annually or per urologist guidance in men over 50